SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-014866
Filing Date
2023-08-14
Accepted
2023-08-14 16:30:31
Documents
64
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q otlk-20230630x10q.htm   iXBRL 10-Q 1495572
2 EX-31.1 otlk-20230630xex31d1.htm EX-31.1 9604
3 EX-31.2 otlk-20230630xex31d2.htm EX-31.2 12100
4 EX-32.1 otlk-20230630xex32d1.htm EX-32.1 9503
  Complete submission text file 0001558370-23-014866.txt   6768642

Data Files

Seq Description Document Type Size
5 EX-101.SCH otlk-20230630.xsd EX-101.SCH 39576
6 EX-101.CAL otlk-20230630_cal.xml EX-101.CAL 43251
7 EX-101.DEF otlk-20230630_def.xml EX-101.DEF 219959
8 EX-101.LAB otlk-20230630_lab.xml EX-101.LAB 341673
9 EX-101.PRE otlk-20230630_pre.xml EX-101.PRE 328316
58 EXTRACTED XBRL INSTANCE DOCUMENT otlk-20230630x10q_htm.xml XML 1290494
Mailing Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830
Business Address 485 ROUTE 1 SOUTH BUILDING F, SUITE 320 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

IRS No.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 001-37759 | Film No.: 231170919
SIC: 2836 Biological Products, (No Diagnostic Substances)